Cycurion receives Nasdaq delisting determination; appeals to Hearings Panel
Cycurion received a Staff Determination Letter from Nasdaq on July 10, 2026, notifying the company that Nasdaq has determined to delist its common stock due to the closing bid price falling below the $1.00 per share minimum for 31 consecutive business days from May 26, 2026 through July 9, 2026. The company is ineligible for the standard 180-calendar day compliance period because it effected a 1-for-30 reverse stock split on October 27, 2025. Trading was expected to be suspended at the opening of business on July 21, 2026, but the company plans to timely request a hearing before the Nasdaq Hearings Panel before the July 17, 2026 deadline, which will stay the suspension and allow the stock to remain listed and trading during the appeal process pending a final Hearings Panel decision.
Key facts
- Nasdaq Staff Determination Letter dated July 10, 2026 determined to delist Cycurion's common stock
- Closing bid price was below $1.00 per share for 31 consecutive business days from May 26, 2026 through July 9, 2026
- 1-for-30 reverse stock split effected on October 27, 2025 made company ineligible for customary 180-calendar day compliance period
- Trading suspension expected at opening of business on July 21, 2026 absent timely hearing request
- Company plans to request hearing before Nasdaq Hearings Panel before July 17, 2026 deadline
- Timely hearing request will stay suspension and Form 25-NSE filing pending Panel decision
- Annual revenue run rate exceeding $28 million
Why it matters
A delisting determination has been issued by Nasdaq; the company's stock remains listed only while its appeal is pending, and there is no assurance the Hearings Panel will grant continued listing or that the company will regain compliance with Nasdaq requirements.
Share
Derived from 8-K filed 2026-07-16. Not investment advice. View the source filing on SEC.gov →